Rigel Pharmaceuticals Inc. Common Stock
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
RIGL Overview
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$1.3200 |
Previous Close Volume |
978620 |
Latest News
- Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition 09 Dec 2024 12:32:43
- Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS 02 Dec 2024 08:32:55
- Rigel to Present at the Jefferies London Healthcare Conference 12 Nov 2024 08:33:42
- Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update 07 Nov 2024 16:04:24
- Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition 05 Nov 2024 09:05:18
- Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update 31 Oct 2024 08:19:26
- Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib) 24 Oct 2024 17:04:16
- Rigel to Present at the 2024 Cantor Global Healthcare Conference 12 Sep 2024 08:19:15
- Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML 05 Sep 2024 07:34:30
- Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan 03 Sep 2024 08:04:57
- Rigel to Participate in Upcoming September Investor Conferences 29 Aug 2024 08:33:35
- Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update 06 Aug 2024 16:04:39
- Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update 30 Jul 2024 08:20:06
- Rigel Announces Reverse Stock Split 25 Jun 2024 08:05:14
- Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application 24 Jun 2024 16:05:22
- Rigel Announces Five Presentations at the EHA2024 Hybrid Congress 14 Jun 2024 03:05:12
- Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting 03 Jun 2024 08:35:27
- Rigel to Present at the Jefferies Global Healthcare Conference 30 May 2024 08:05:12
- Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress 23 May 2024 17:20:30
- Rigel Reports First Quarter 2024 Financial Results and Provides Business Update 07 May 2024 16:20:31
- Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update 30 Apr 2024 08:21:06
- Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma 04 Apr 2024 08:05:35
- Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer 12 Mar 2024 08:21:01
- Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update 05 Mar 2024 16:39:59
- Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update 27 Feb 2024 08:06:06
- Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO® 22 Feb 2024 08:05:52